Galantamine
Anticholinesterases
- Drug class
- Anticholinesterases
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 66
- FDA reports (12 mo)
- 140
Overview
Galantamine is an active pharmaceutical ingredient in the Anticholinesterases group (N06DA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 38 | May 22, 2026 |
| CA Canada | Health Canada | 25 | December 19, 2025 |
| US United States | FDA | 3 | January 19, 2026 |
GBUnited Kingdom· MHRA
38 products
Uses
Acumor XL is indicated for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type.
How to take
CACanada· Health Canada
25 products
Uses
PAT-galantamine ER (galantamine hydrobromide extended release capsules) is indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer’s type. Galantamine has not been studied in controlled clinical trials for longer than 6 months.
PAT-galantamine ER should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer’s disease. 1 Pediatrics Pediatrics (<18 years of age): No data are available in children.
Therefore, the use of PAT- galantamine ER is not recommended in children under 18 years of age. 4 Geriatrics).
How to take
USUnited States· FDA
3 products
Uses
1 INDICATIONS AND USAGE Galantamine hydrobromide extended-release capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Galantamine hydrobromide is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type ( 1 )
How to take
Drug interactions
Known interactions involving Galantamine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 385. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL045691333 · revised November 28, 2025
- [2]Health Canada (DPD) · 02316943 · revised December 19, 2025
- [3]FDA DailyMed · 0f74a146-f6ee-49… · revised September 12, 2025 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.